Group program to promote post-traumatic growth for adults with breast, colorectal, or head and neck cancer in Greece
Official title: A Manualized Post-Traumatic Growth Intervention for People With Cancer in Greece - IC-Growth. The Overarching Aim of IC-Growth is to Promote Psychosocial Care and Support for People With Cancer Using Acceptance and Committment Therapy.
Run by Centre for Research and Technology Hellas · NCT07108517 · Data updated 2026-11-12
This project will try a manualized, group-based ACT program to help Greek adults who finished chemotherapy for breast, colorectal, or head and neck cancer increase post-traumatic growth and quality of life.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Centre for Research and Technology Hellas Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Thessaloniki) |
| Status | Recruiting |
| Started | May 1, 2025 |
| Main results expected | November 30, 2025 |
| Study ends | December 30, 2025 |
| Registry record updated | August 7, 2025 |
| Trial ID | NCT07108517 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) in Greece with a diagnosis of breast, colorectal, or head and neck cancer who have completed planned chemotherapy, are within five years of initial diagnosis, can read and speak Greek, can give informed consent, and are not currently in active psychiatric treatment are eligible.
✕Probably not a fit
People in active psychological or psychiatric treatment, with unmanaged serious mental illness, severe cognitive impairment, recent relapse or another cancer within five years, non-Greek speakers, or with less than one year life expectancy are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
IC-Growth is a 24-month, multidisciplinary program that develops and tests a manualized intervention to promote post-traumatic growth (PTG) in adults with breast, colorectal, and head and neck cancers. The work includes a systematic review, a cross-sectional study of 210–240 patients measuring PTG, quality of life, biological markers and psychological variables, and a randomized controlled trial across two Greek hospitals. The RCT will randomize roughly 70–80 participants per cancer type to a six-to-eight week, 90-minute weekly group ACT-based PTG intervention versus standard care. Results will be used to create best-practice recommendations and inform health policy for psychosocial survivorship care.
Why it matters
Potential benefit: If successful, the intervention could increase resilience and improve quality of life after cancer by helping survivors achieve psychological growth beyond their pre-diagnosis functioning.
How similar studies have gone: Small trials and ACT-based psychosocial programs in cancer and other trauma settings have shown feasibility and some benefits for coping and quality of life, but large RCT evidence specifically targeting PTG in cancer is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults (≥ 18 years) 2. Having a diagnosis of a. Breast Cancer, b. Colorectal Cancer, or c. Head and Neck Cancer. 3. Having concluded the planned chemotherapy courses and related hospital admissions 4. Having no more than 5 years since the initial diagnosis. Exclusion Criteria: 1. Being in active psychological or psychiatric treatment 2. Having an unmanaged mental health difficulty 3. Having a severe cognitive impairment 4. Being unable to give informed consent 5. Being unable to speak or read Greek 6. Having one or more relapses 7. Diagnosed with another type of cancer within 5 years prior to recruitment. 8. Having less than one-year life expectancy
Where it's running
-
AHEPA University Hospital
Thessaloniki, Greece Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Cutting down ultra-processed foods for people at high cancer risk
This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.
-
Digital app to support oncologist‑initiated genetic testing
This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.
-
EXoPERT EMERALD: a blood test using AI on extracellular vesicles to detect early lung, breast, colorectal, pancreatic, and ovarian cancers.
This test tries to detect early lung, breast, colorectal, pancreatic, and ovarian cancers from a single blood sample by using AI to read Raman spectroscopy patterns of tiny particles called extracellular vesicles.
-
Virtual exercise program to preserve function and prevent disability during chemotherapy
This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.
-
IDOV-Immune for advanced solid tumors
This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.
-
Evaluating new imaging technology for cancer radiation therapy
This study is testing a new imaging technology for cancer radiation therapy to see if it can provide better pictures than the standard method, helping patients get more effective treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.